About BlueRock Therapeutics
BlueRock focuses on stem cell research to regenerate heart muscles after a heart attack, and to develop therapies for Parkinson’s disease.
Driven by a vision to liberate patients from degenerative disease, BlueRock Therapeutics is ushering in a new era of cell-based medicines. Founded in 2016, BlueRock and its team of preeminent scientists are pioneering cell therapies that restore critical natural functions in the body, with an initial focus on severe brain and heart conditions. BlueRock’s culture is defined by scientific transparency, the highest ethical standards and an urgency to bring transformative treatments to all who would benefit.
Founder: Gordon Keller and Lorenz Studer
CEO: Emile Nuwaysir
CTO: Robert Deans
12 articles with BlueRock Therapeutics
Appointment strengthens the leadership team and accelerates the company's establishment of its novel Cell+Gene platform
It’s hard to believe 2018 is half over. There have been plenty of interesting and important stories in the biopharma space this year. Here’s a look at our top 10 stories so far, counting down from 10 to the number one story.
BlueRock Therapeutics Establishes R&D Site in New York City and Formalizes Collaboration with Memorial Sloan Kettering Cancer Center
Company Receives $1 Million Incentive Through Economic Development Initiative of New York State and Empire State Development
BlueRock Therapeutics, which has locations in Toronto, NYC and Cambridge, Mass., rocketed to existence in December 2016 with $225M in venture funding to focus on regenerative medicine, using iPSC therapies.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
BlueRock Therapeutics Announces Appointment of Derek Hei, Ph.D. as Senior VP, Manufacturing, Quality and Regulatory
Dr. Hei brings to BlueRock over twenty years of experience developing breakthrough cell and gene therapies from research through clinical trials.
BlueRock was founded in 2016 when Versant Ventures and Bayer invested $225 million in a Series A financing.
BlueRock Therapeutics And Universal Cells Enter Collaboration And License Agreement To Generate Gene-Edited iPS Cell Lines
BlueRock Therapeutics Expands Toronto Presence With R&D And Manufacturing Hub, Appoints Key R&D Leadership